Article
Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer.
PloS one - 1 Jan 2013
Jiang Guiyang, Fan Chuifeng, Zhang Xiupeng, Dong Qianze, Wang Liang, Liu Yang, Dai Shundong, Yang Lianhe, Zhang Yong, Yu Juanhan, Wang Enhua
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) mutation status is the most valuable indicator in the screening of non-small-cell lung cancer (NSCLC) patients for tyrosine kinase inhibitor (TKI) therapy. Accurate, rapid and economical methods of detecting EGFR mutations have become important. The use of two mutation-specific antibodies targeting the delE746-A750 mutation in exon 19 and L858R mutation in exon...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.